2028 FDA Approval Licensing Trials 
The Pharma Data
JANUARY 9, 2021
. A follow-on procurement contract with HHS is expected for the delivery of raxibacumab, the Company’s Food and Drug Administration-approved anthrax monoclonal antibody therapeutic, to the Strategic National Stockpile (SNS). FOOTNOTES. (1)
The Pharma Data
NOVEMBER 4, 2020
Reaffirmed c linical trial results from study of VASCEPA in China are expected by year end 2020 : Assuming positive results from this study conducted by Amarin’s commercial partner for VASCEPA in China, regulatory submission in China could follow promptly thereafter. This compares with licensing and royalty revenue of $0.2
Expert insights. Personalized for you.
52 
Let's personalize your content